StemCell Therapy

(RTTNews.com) - Cytori Therapeutics (CYTX) said Wednesday it has obtained approval to sell the Celution 800 System in Russia for various medical uses.

These clinical uses are based on those in the current European CE Mark, and include the use of the Celution system and its output of adipose-derived stem and regenerative cells for plastic surgery and select soft tissue therapies, Cytori said.

The company said the Celution system and related products will be sold into Russia for these indications exclusively through its distribution partner Human Stem Cells Institute of Moscow (HSCI).

"This regulatory achievement and the distribution partnership with HSCI gives us immediate access to the Russian market through an established and scientifically driven organization with a sales and marketing team already trained and knowledgeable in cell therapy," said Clyde Shores, Executive Vice-President of Marketing & Sales.

"We anticipate beginning to see the incremental impact from Russian sales starting in the second half of 2012. This approval is an important achievement and helps fulfill our stated 2012 goal to obtain additional market approvals for our technology."

For comments and feedback: contact editorial@rttnews.com

http://www.rttnews.com

Link:
Cytori Obtains Russian Approval To Sell Celution 800 System - Quick Facts

This entry was posted on May 31, 2012 at 2:16 am and is filed under Stem Cell Russia. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |